Kiniksa 10-Q: Q3 Revenue Up 58% to $286.0M, Net Income $47.3M, $568.8M Cash
KNSA has more than doubled off its 52-week low of $35.2 on elevated volume (3.9× avg).
Summary
Kiniksa's Q3 10-Q shows revenue of $286.0M (up from $180.9M), net income of $47.3M and $568.8M in cash and investments, funding the KPL-387 Phase 3 program without new financing.
Key Events · Earnings and Guidance · KNSA
-
Q3 Revenue Jumps 58%
Product revenue, net was $285,970K for the three months ended September 30, 2026 versus $180,855K a year earlier, driven by more patients on ARCALYST therapy.
-
Net Income Nearly Triples
Net income was $47,345K ($0.56 diluted per share) versus $18,435K ($0.23) a year ago; nine-month net income reached $95,369K.
-
Cash Funds Phase 3 Without Raise
Cash, cash equivalents and short-term investments totaled $568.8M at September 30, 2026, alongside $144,941K of nine-month operating cash flow; management says this funds the operating plan for at least the next 12 months.
-
KPL-387 Spend Ramps
Direct KPL-387 R&D was $17,250K in Q3 and $54,844K year-to-date as the Phase 3 PASTORALE trial enrolls; data is expected in the second half of 2027.
Analysis · KNSA · Life Sciences
The headline numbers were already out via the morning press release, but the 10-Q is where the quality of the quarter shows: revenue of $286.0M against $180.9M a year ago, operating income of $54.2M and net income of $47.3M, with $568.8M of cash and investments on the balance sheet. That cash plus $144.9M of nine-month operating cash flow funds the KPL-387 Phase 3 program — $54.8M spent year-to-date and rising — without needing to raise money. The offset is cost: total operating expenses grew to $231.7M from $156.8M as the company builds out commercial and clinical infrastructure, so margin expansion depends on ARCALYST volume continuing to outrun that spend.
How filings like this one have moved
In the 30 days to Oct 27, 2026, 29.9% of the 1374 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.12%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, KNSA was trading at $89.40 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7B. The 52-week trading range was $35.20 to $90.80. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.